Q1 EPS Forecast for Viridian Therapeutics Reduced by Analyst

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for Viridian Therapeutics in a research note issued to investors on Monday, March 30th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($1.16) per share for the quarter, down from their previous estimate of ($1.11). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q2 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.17) EPS and FY2026 earnings at ($4.75) EPS.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $15.75 million.

A number of other equities analysts have also recently issued reports on the stock. UBS Group started coverage on shares of Viridian Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. William Blair assumed coverage on shares of Viridian Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating for the company. Wells Fargo & Company cut their target price on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Needham & Company LLC reduced their price target on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a report on Monday. Finally, Wedbush lowered their price target on Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating for the company in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.21.

Viridian Therapeutics Trading Down 2.1%

NASDAQ:VRDN opened at $19.15 on Wednesday. The firm has a market capitalization of $1.96 billion, a P/E ratio of -5.82 and a beta of 1.16. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The company has a fifty day moving average of $28.90 and a 200 day moving average of $27.83. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd purchased a new stake in shares of Viridian Therapeutics in the 3rd quarter worth about $35,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Viridian Therapeutics during the fourth quarter valued at about $36,000. Farther Finance Advisors LLC increased its position in shares of Viridian Therapeutics by 332.1% during the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after buying an additional 1,491 shares during the period. Bessemer Group Inc. increased its position in shares of Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after buying an additional 1,886 shares during the period. Finally, Larson Financial Group LLC bought a new position in Viridian Therapeutics in the third quarter worth about $52,000.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Company reported positive topline results from the Elegrobart Phase 3 REVEAL‑1 trial in active thyroid eye disease — the clinical readout is a fundamental positive for long‑term drug value and commercial potential. Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and set a $22 target while revising Q1–Q4 and FY2026 EPS estimates (small mix of raises and cuts) — shows continued analyst support but revised modeling reflects higher near‑term costs/assumptions. HC Wainwright estimate and rating note
• Neutral Sentiment: Recent intraday swings included a sharp bounce the prior session (Zacks noted a 5.6% jump on higher‑than‑average volume), highlighting that VRDN is trading on headline events and momentum as much as fundamentals. Viridian Therapeutics (VRDN) Soars 5.6%
• Negative Sentiment: Shares plunged pre‑market on headlines that followed the Phase 3 disclosure (market reaction suggests investors were disappointed by details beyond topline, or that expectations were higher), triggering heavy selling and volatility. VRDN stock plummeted 41% pre-market today
• Negative Sentiment: Multiple firms trimmed price targets (Goldman Sachs to $36, Wells Fargo to $20 with an equal‑weight, Wedbush to $37, HC Wainwright down to $22) — these cuts signal reduced near‑term upside in sell‑side models and likely contributed to downward pressure. Broker price target updates
• Negative Sentiment: Several news outlets highlighted that shares fell despite the positive topline, suggesting investor concerns about safety details, subgroup results, magnitude of benefit, or commercial assumptions — expect continued headline‑driven trading until full data and guidance are clarified. Viridian Therapeutics stock tumbles despite trial success

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.